The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff

A seismic shift is underway in the global pharmaceutical landscape. With the patent expiry of semaglutide—the active ingredient behind blockbuster drugs like Ozempic and Wegovy—in India, select regulated markets, and emerging economies, a massive revenue opportunity exceeding ₹50,000 crore (approximately $6 billion) has opened up for generic drugmakers. According to a recent report by Systematix Institutional Research, this window, unfolding over the next 12–15 months, will be fiercely contested by 10 to 15 Indian and global generic players eager to capture a share of one of the most lucrative markets in modern medicine.

Semaglutide, a GLP-1 receptor agonist, has revolutionized the treatment of type 2 diabetes and obesity, generating tens of billions in annual sales worldwide. But its high cost—often unaffordable without insurance—has limited access for millions. The entry of generics is expected to slash prices by 30–50% initially, with potential reductions of up to 70–75% over time, dramatically accelerating adoption across income levels.

In India, where generic versions are slated for launch in Q1 of FY27, the impact could be transformative. The market alone is projected to generate ₹10–20 billion ($120–240 million) in incremental revenue, while also boosting overall Indian Pharmaceutical Market (IPM) growth by 0.5–1%. Already, Alkem Laboratories, Dr. Reddy’s Laboratories, and Sun Pharma have secured domestic regulatory approvals, positioning them as early movers. Zydus Lifesciences, meanwhile, is pursuing a differentiated injectable formulation that could offer a competitive edge despite its smaller diabetes footprint.

Beyond India, regulated markets like Canada and Brazil represent the biggest financial prize—estimated at ₹45 billion ($540 million). The combined semaglutide market in these two countries totals nearly $2 billion annually. Assuming generics capture 50% market share with 50% price erosion, the addressable opportunity stands at roughly $500 million. Dr. Reddy’s is poised to become the first Indian generic entrant in Canada, while Sun Pharma may enjoy first-mover advantage in Brazil, thanks to existing infrastructure and regulatory pathways.

In emerging markets, growth is expected to be steadier but more sustainable, with lower regulatory hurdles. Companies like Sun Pharma, Dr. Reddy’s, Alkem, Biocon, and OneSource Specialty Pharma are best positioned here, leveraging established diabetes portfolios and distribution networks.

Notably, the ripple effects extend beyond active pharmaceutical ingredients. Shaily Engineering Plastics, a key global supplier of pen injector devices used in GLP-1 therapies, is set to benefit significantly as generic launches scale up—highlighting how entire supply chains stand to gain.

Despite the frenzy, success won’t be guaranteed. Timely regulatory approvals, manufacturing scale, and pricing strategy will determine winners. Moreover, while market leadership in the GLP-1 segment is likely to remain concentrated among 5–10 dominant players, intense competition will pressure margins over time.

For patients, however, the outcome is unequivocally positive: life-changing therapy is about to become vastly more accessible. As patents fall, a new era begins—not just of affordability, but of democratized metabolic health. And in this high-stakes race, Indian pharma isn’t just participating—it’s leading the charge.